Skip to main content
. 2013 Jan 15;121(12):2340–2346. doi: 10.1182/blood-2012-11-465583

Figure 1.

Figure 1

Failure-free survival after second-line treatment of chronic GVHD. The dark gray area represents treatment failure due to recurrent malignancy. The light gray area represents treatment failure due to nonrelapse mortality (NRM), and the black area represents treatment failure due to onset of third-line systemic treatment. The white area represents FFS. The dashed line represents cumulative incidence of successful withdrawal of all systemic immunosuppressive treatment (IST) during second-line treatment.